Previous close | 0.2500 |
Open | 0.2500 |
Bid | 0.0000 |
Ask | 0.7500 |
Strike | 110.00 |
Expiry date | 2023-06-16 |
Day's range | 0.2500 - 0.2500 |
Contract range | N/A |
Volume | |
Open interest | 48 |
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Key Insights Becton Dickinson's estimated fair value is US$258 based on 2 Stage Free Cash Flow to Equity Current share...
BD's (BDX) latest cell sorting technology is expected to speed up the process of cell sorting and allow researchers to answer complex biological questions.
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
BD's (BDX) receipt of the latest FDA approval is likely to improve laboratory workflow.
Key Insights Given the large stake in the stock by institutions, Becton Dickinson's stock price might be vulnerable to...
BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal second quarter.
Becton, Dickinson and Company CEO and President Tom Polen joins Yahoo Finance Live to discuss company earnings, growth opportunities in the home test kit market, biotech drugs, strong demand in the weight loss market, and the outlook for Becton Dickinson.
Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Most readers would already be aware that Becton Dickinson's (NYSE:BDX) stock increased significantly by 6.7% over the...
Becton Dickinson (BDX) delivered earnings and revenue surprises of 4% and 3.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited Q2 sales.
Investors are optimistic about Edwards Lifesciences (EW) on the increased adoption of its premium RESILIA technologies.
Key Insights Using the 2 Stage Free Cash Flow to Equity, Becton Dickinson fair value estimate is US$262 Becton...
Becton, Dickinson, Raytheon Technologies and Palantir Technologies are part of the Zacks Screen of the Week article.
BDX vs. WST: Which Stock Is the Better Value Option?
BD's (BDX) latest launch is expected to advance its vision of a One-Stick Hospital Stay by improving the first-stick success in IV placements.
Viewing insider transactions for Becton, Dickinson and Company's ( NYSE:BDX ) over the last year, we see that insiders...
Here is how Avanos Medical (AVNS) and Becton Dickinson (BDX) have performed compared to their sector so far this year.
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Becton Dickinson's (NYSE:BDX) stock up by 4.4% over the past month. As most would know, long-term fundamentals have a...
BDX vs. WST: Which Stock Is the Better Value Option?
It's easy to feel disappointed if you buy a stock that goes down. But sometimes a share price fall can have more to do...
Here are two Dividend Aristocrats that are top-rated Zacks stocks at the moment and can offer unique exposure and diversification to investors' portfolios.
Key Insights The projected fair value for Becton Dickinson is US$263 based on 2 Stage Free Cash Flow to Equity Current...